Food Allergy Institute, Latitude and Curex
What each one actually offers, where the clinics are, what they publish about price and outcomes — and how to read the success rates, ours included.
They are not substitutes for each other. Two decisive differences: geography — both clinic providers are concentrated in California and New York — and what each method does. Clinic oral immunotherapy raises reaction thresholds substantially more than sublingual dosing does. If you can reach a clinic and sustain the schedule, that is the stronger option on the evidence, and we would rather say so than win a comparison we do not deserve to win.
Medically reviewed by Dr. Chet Tharpe, M.D. · Last reviewed August 2026
Side by side
What each provider publishes
Food Allergy Institute
- Method
- Tolerance Induction Program — real foods, starting from structurally similar non-allergenic proteins rather than the allergen itself
- Where
- California and New Jersey; Dallas affiliate; a Tri-State location opening 15 Sept 2026
- Published price
- $979/month; $1,079 for ages 26+
- Duration
- 2.5 to 4 years
- Ages
- 15 months to 50 years
- Published outcome
- “99% success rate after completing TIP”
Also publishes “<1% reaction rate for the duration of TIP”
Latitude Food Allergy Care
- Method
- Clinic oral immunotherapy
- Where
- 9 California and 4 New York locations
- Published price
- Not published; states it accepts most insurance plans
- Duration
- Not published
- Ages
- Not published
- Published outcome
- “98% of patients under 4 … 94% of patients of all ages achieved desensitization”
Labelled on their own site as “Internal data, 2026”
Curex
That’s us- Method
- Sublingual immunotherapy taken at home, under remote clinical supervision
- Where
- Remote, nationwide
- Published price
- $149/month food allergy plan
- Duration
- Ongoing
- Ages
- From 2
- Published outcome
- No food-specific outcome data published
Our published cohort covers environmental allergies, not food
Every figure above is what the provider published on its own site, checked August 2026. Where a provider publishes nothing, the row says so rather than estimating. Prices and claims change — confirm with each provider, including us, before enrolling.
The important part
How to read those success rates — ours included
“After completing” is the load-bearing phrase. A 99% success rate among people who finished a two-and-a-half to four-year programme tells you about the people who finished. It does not tell you how many started. No provider in this space routinely publishes that number, and it is the first question worth asking any of them — including on a sales call with us.
“Internal data” is Latitude’s own label on its figures, and an honest one. It means these are their records rather than a peer-reviewed result. That is not a criticism; it is a description, and they made it themselves.
And ours: Curex has published no food allergy outcome data. The real-world study our clinicians published covers 2,897 patients treated for environmental allergies — pollens, dust mite, pet dander. Applying it to food would misrepresent what was measured, so we do not, and you should discount any page of ours that seems to.
What actually decides it
Two questions, not the marketing
- Can you reach a clinic? Both clinic providers are concentrated in California and New York. For most of the country that means travel, repeatedly, for years — here is what the geography actually looks like.
- What does each method do? In a direct comparison in peanut-allergic children, oral immunotherapy raised the reaction threshold roughly 141-fold at 12 months against roughly 22-fold for sublingual. If you can reach a clinic and sustain the schedule, the threshold evidence favours clinic OIT.
Honest routing
Where we fit, and where we do not
Curex is a reasonable fit
- No clinic within reasonable reach of where you live
- A schedule that cannot absorb years of clinic visits and post-dose rest windows
- A preference for a smaller, better-tolerated intervention that is realistic to sustain
- You want treatment supervised by a clinician without relocating your week around it
Go elsewhere
- A history of anaphylaxis, until an in-person assessment says otherwise
- Severe or poorly controlled asthma alongside the food allergy
- You can reach a clinic OIT programme, can sustain it, and want the largest achievable threshold rise
- You need a food challenge — those happen in clinic, on every protocol including ours
Context
The withdrawal levelled one thing
The established clinic programmes largely ran their own off-label protocols rather than the branded product, so Palforzia leaving the US market on 31 July 2026 did not disrupt them directly.
What it changed is the framing. With no FDA-approved food immunotherapy on the market, every programme described here — clinic and remote alike — is off-label. Off-label status no longer distinguishes one provider from another, and anyone using it as a differentiator is describing the whole field.
❓Frequently Asked Questions
Food Allergy Institute describes TIP as a personalised, data-driven programme using real foods that, in their words, "Never Begins With Direct Allergen Exposure" — it starts by escalating structurally similar non-allergenic proteins before approaching the allergen itself. Standard oral immunotherapy escalates the allergen directly from the start. FAI publishes a 2.5 to 4-year duration, ages 15 months to 50 years, and says it assesses 130+ allergens.
Carefully, and this applies to every provider including us. Food Allergy Institute publishes "99% success rate after completing TIP". The wording matters: the denominator is people who completed a programme lasting two and a half to four years, not everyone who started. Providers do not generally publish how many begin and stop. Latitude publishes 98% desensitisation for patients under four and 94% across all ages, labelled on their own site as "Internal data, 2026" — their own honest flag that this is not a peer-reviewed result. Neither figure is evidence of dishonesty. Both are figures whose denominator you should ask about.
Nothing, and we would rather say that plainly than imply otherwise. The real-world study Curex clinicians published covers 2,897 patients treated for environmental allergies — pollens, dust mite, pet dander — not food allergy. Applying it to food would misrepresent what was measured. For food allergy specifically, the evidence we rely on is the published literature on sublingual immunotherapy generally, which shows a smaller rise in reaction thresholds than oral immunotherapy achieves.
If you live within reach of a clinic, can sustain a multi-year schedule of visits, and want the largest achievable rise in reaction threshold, a clinic oral immunotherapy programme is the stronger option on the evidence, and we are not going to pretend otherwise. If no clinic is reachable, or the schedule of an OIT protocol is not compatible with your family, sublingual immunotherapy under remote supervision is a real option with a smaller effect. If there is a history of anaphylaxis or severe asthma, that assessment happens in person regardless of which route you are considering.
Food Allergy Institute publishes $979 per month, or $1,079 for ages 26 and over. Over a published 2.5 to 4-year course that is roughly $29,000 to $47,000 before travel. Latitude does not publish prices and states it accepts most insurance plans, so your cost depends on your coverage. Curex lists a food allergy plan at $149 per month. Those are not like-for-like: the clinic programmes deliver a substantially larger rise in reaction threshold, and cost per month is a poor way to compare treatments that do different amounts of work. Prices change — confirm current figures with each provider.
Not directly, because the established clinic programmes largely ran their own off-label protocols rather than the branded product. It affects the wider field: with Palforzia withdrawn from the US market on 31 July 2026, no FDA-approved food immunotherapy exists, so every programme described here — clinic and remote alike — is off-label. Off-label is no longer a distinguishing feature of one provider over another.
If you experience sudden difficulty breathing, throat swelling, or other signs of anaphylaxis, call 911. A prescribed epinephrine auto-injector is the first-line treatment — not antihistamines.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Sources: foodallergyinstitute.com and latitudefoodallergycare.com, published figures checked August 2026; randomized comparison of sublingual versus oral immunotherapy for peanut allergy (PMID 25528358). Curex is one of the providers described here — read this page with that in mind, and check the claims against each provider’s own site.
Keep reading
- Is Curex legit?The company, the evidence, and the concerns worth knowing — including full context on the 2025 FDA warning letter.Read
- How Curex worksThe treatment process end to end, from at-home testing to daily drops.Read
- Curex reviewsWhat patients actually report — both clusters, including the complaints.Read
- Is Curex worth the money?Plan pricing against allergy-shot costs, and who it is not worth it for.Read
- Evidence & guidelinesWhat the FDA approved, what the AAAAI/ACAAI practice parameter does and does not endorse, and what has been added since.Read
- Providers comparedCurex, Wyndly and Nectar on published prices, guarantees and evidence — including where a competitor is ahead.Read